Activation test for diagnosis of heparin-induced thrombocytopenia
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SIEMENS HEALTHCARE DIAGNOSTICS PRODS
- Publication Date
- 2021-09-17
Smart Images

Figure 1
Abstract
Description
technical field
[0001] The present invention is in the field of in vitro diagnostics and relates to a functional, easily automatable test for the determination of heparin-induced thrombocytopenia. Background technique
[0002] Heparin-induced thrombocytopenia (HIT) is a thrombotic disorder that may occur during heparin therapy and may result in life-threatening thromboembolic complications. Patients produce antibodies that bind to a complex of heparin and platelet factor 4 (PF4), known as anti-PF4 / heparin complex antibodies. In vivo, the antibody-bound PF4 / heparin complex binds to the platelet surface and causes activation of the platelet. This results in a decrease in platelet counts and an increased risk of thromboembolism.
[0003] There are two main test principles used in the diagnosis of HIT. The first test principle is based on the direct detection of anti-PF4 / heparin complex antibodies in a patient's body fluid sample. To this end, the sample is contacted with a ...